Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Infectious Disease
•
Transplant Infectious Disease
How do you dose maribavir in pediatric patients and on what is that based?
Related Questions
Under which circumstances is there a role for reduction in immunosuppression post-SOT in a patient with recurrent CMV viremia and/or disease?
Are there instances when you use letermovir without the addition of acyclovir when managing a kidney transplant recipient for CMV prophylaxis?
Is the combination of a negative BAL PJP PCR and normal fungitell enough to rule out PJP pneumonia in an at-risk non-HIV patient?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Would you consider antifungal prophylaxis for immunocompromised patients with COVID-19 requiring mechanical ventilation, considering the high risk of invasive pulmonary aspergillosis in patients with severe COVID-19?
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
What are your top takeaways from ID Week 2024?
Are you currently offering pemivibart (Pemgarda) for pre-exposure prophylaxis against COVID-19 to immunocompromised patients?
What is your preferred dosing of IV ganciclovir for CMV disease in immunocompromised patients?
Would you transition from IV to oral antibiotics in a solid organ transplant recipient with uncomplicated gram-negative bacteremia?
